ArticleArchives of osteoporosis2022

Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada.

Ron Goeree et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.